Product nameAnti-BRG1 antibody
See all BRG1 primary antibodies
DescriptionRabbit polyclonal to BRG1
SpecificityWe have conflicting data about the performance of this antibody in ChIP. Publications have reported positive results with this antibody using ChIP application, however we also have customer data indicating certain batches of this antibody did not work in ChIP in their hands. If you require any further information or assistance please contact Abcam Scientific Support Team.
Tested applicationsSuitable for: IP, WBmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Mouse, Human
Predicted to work with: Rat
Synthetic peptide corresponding to Human BRG1 aa 1400-1500 conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in the following cell lysate preparations: Jurkat; Jurkat nuclear; HepG2 nuclear.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab4081 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration. PubMed: 20522713|
|WB||1/500 - 1/1000. Detects a band of approximately 235 kDa (predicted molecular weight: 185 kDa).|
FunctionTranscriptional coactivator cooperating with nuclear hormone receptors to potentiate transcriptional activation. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a post-mitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to post-mitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth. SMARCA4/BAF190A may promote neural stem cell self-renewal/proliferation by enhancing Notch-dependent proliferative signals, while concurrently making the neural stem cell insensitive to SHH-dependent differentiating cues (By similarity). Also involved in vitamin D-coupled transcription regulation via its association with the WINAC complex, a chromatin-remodeling complex recruited by vitamin D receptor (VDR), which is required for the ligand-bound VDR-mediated transrepression of the CYP27B1 gene. Acts as a corepressor of ZEB1 to regulate E-cadherin transcription and is required for induction of epithelial-mesenchymal transition (EMT) by ZEB1.
Tissue specificityColocalizes with ZEB1 in E-cadherin-negative cells from established lines, and stroma of normal colon as well as in de-differentiated epithelial cells at the invasion front of colorectal carcinomas (at protein level).
Involvement in diseaseDefects in SMARCA4 are the cause of rhabdoid tumor predisposition syndrome type 2 (RTPS2) [MIM:613325]. RTPS2 is a familial cancer syndrome predisposing to renal or extrarenal malignant rhabdoid tumors and to a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumors. Rhabdoid tumors are the most aggressive and lethal malignancies occurring in early childhood.
Sequence similaritiesBelongs to the SNF2/RAD54 helicase family.
Contains 1 bromo domain.
Contains 1 helicase ATP-binding domain.
Contains 1 helicase C-terminal domain.
Contains 1 HSA domain.
modificationsPhosphorylated upon DNA damage, probably by ATM or ATR.
- Information by UniProt
- ATP dependent helicase SMARCA4 antibody
- ATP-dependent helicase SMARCA4 antibody
- BAF 190 antibody
Lane 1: Wild-type HAP1 cell lysate (40 µg)
Lane 2: BRG1 knockout HAP1 cell lysate (40 µg)
Lane 3: HeLa cell lysate (40 µg)
Lane 4: K562 cell lysate (40 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab4081 observed at 240 kDa. Red - loading control, ab18058, observed at 124 kDa.
ab4081 was shown to recognize BRG1 when BRG1 knockout samples were used, along with additional cross-reactive bands. Wild-type and BRG1 knockout samples were subjected to SDS-PAGE. Ab4081 and ab18058 (loading control to Vinculin) were diluted at 1/500 and 1/10,000 dilution respectively and incubated overnight at 4C. Blots were developed Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) with Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1:10,000 dilution for 1 hour at room temperature before imaging.
All lanes : Anti-BRG1 antibody (ab4081) at 1 µg/ml
Lane 1 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate
Lane 2 :
Jurkat nuclear extract lysate (ab14844)
Lane 3 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
Lane 4 :
HepG2 nuclear extract lysate (ab14660)
Lysates/proteins at 10 µg per lane.
All lanes : IRDye 680 Conjugated Goat Anti-Rabbit IgG (H+L) at 1/10000 dilution
Performed under reducing conditions.
Predicted band size: 185 kDa
Observed band size: 235 kDa why is the actual band size different from the predicted?
Additional bands at: 40 kDa. We are unsure as to the identity of these extra bands.
Rabbit polyclonal to BRG1 (ab4081) at 1/500 on HeLa Nuclear extract (20 ug per lane).
Lane 1: ab4081 (1/500)
Lane 2: ab4081 (1/500) + blocking peptide (1 ug)
Secondary antibody: Goat anti-rabbit (HRP) - ab6721
Whole cell lysate prepared from HeLa cells was loaded at 150000 cells.
ab4081 used at a 1/1000 dilution.The secondary used was an HRP conjugated donkey polyclonal used at a 1/5000 dilution.
This product has been referenced in:
- Del Gaudio N et al. BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. Cell Death Dis 10:338 (2019). Read more (PubMed: 31000698) »
- Gowda P et al. Mutant Isocitrate Dehydrogenase 1 Disrupts PKM2-ß-Catenin-BRG1 Transcriptional Network-Driven CD47 Expression. Mol Cell Biol 38:N/A (2018). Read more (PubMed: 29463646) »